Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 19/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127692 | 1.00 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL29702219 | 1.00 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14528347 | 1.00 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14528345 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14276543 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL5124599 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL5382521 | 0.88 | NPY5R (0.81) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14408821 | 0.88 | NPY5R (0.81) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14276589 | 0.88 | NPY5R (0.83) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL5130637 | 0.88 | NPY5R (0.83) | NPY5RADRB2CYP3A4HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2611427-B1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARM INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170246179-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170096398-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9365521-B2 | Non-hygroscopic salts of 5-HT2C agonists | ARENA PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160151381-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9248133-B2 | Salts of lorcaserin with optically active acids | ARENA PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140148442-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. | 2014-05-29 | — | — | US | disclosed |
| US-20130317005-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | Arena Pharmaceuticals ,Inc | 2013-11-28 | — | — | US | disclosed |
| US-20130315994-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2013-11-28 | — | — | US | disclosed |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC | 2013-11-21 | — | — | US | disclosed |
| WO-2008137270-A1 | METHODS OF DIAGNOSING AND MONITORING OF NPY Y5 BASED DISORDERS | H. LUNDBECK A/S (DK) | 2008-11-13 | — | — | WO | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246179-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | HTR2C, HTR2A, HTR3C | NPY5R 57/4885ADRB2 37/4885CYP3A4 468/4885 |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | NPY5R 57/4885ADRB2 37/4885CYP3A4 468/4885 |
| US-20160151381-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | CEL, HTR7, HTR1A | NPY5R 452/4885ADRB2 460/4885CYP3A4 721/4885 |
| US-20130315994-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | HTR2C, HTR2A, HTR3C | NPY5R 57/4885ADRB2 37/4885CYP3A4 468/4885 |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | NPY5R 57/4885ADRB2 37/4885CYP3A4 468/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ADRB2 124/4885CYP3A4 1350/4885 |
| US-20140148442-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | NPY5R 81/4885ADRB2 57/4885CYP3A4 540/4885 |
| US-20130310369-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | CEL, HTR7, HTR1A | NPY5R 452/4885ADRB2 460/4885CYP3A4 721/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | NPY5R 57/4885ADRB2 37/4885CYP3A4 468/4885 |
| US-20170096398-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | NPY5R 100/4885ADRB2 37/4885CYP3A4 1361/4885 |
| US-20130317005-A1 | NON-HYGROSCOPIC SALTS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | NPY5R 100/4885ADRB2 37/4885CYP3A4 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.